Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L‐Amino Acid Decarboxylase Deficiency Using an MR ‐Compatible Cannula: 48 Weeks of Follow‐Up
Journal of Inherited Metabolic Disease · 2026-03 · 49 (2)
DOI: 10.1002/jimd.70151 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 22.02.2026. Verfasst von Daniel J Curry und 22 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Neurosurgery, Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Aromatic-L-Amino-Acid Decarboxylases, Genetic Therapy, Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PTC Therapeutics.
Abstract (Originalsprache)
Aromatic ʟ‐amino acid decarboxylase (AADC) deficiency is a rare pediatric neurotransmitter disorder that typically necessitates lifelong care, and that carries a risk of childhood mortality. Eladocagene exuparvovec gene therapy is designed to restore AADC production. Study GT‐002 (NCT04903288) is a phase 2, multicenter, open‐label trial assessing the pharmacodynamics, safety, and efficacy of eladocagene exuparvovec administered to the putamen bilaterally in pediatric patients with AADC deficiency using a magnetic resonance (MR)‐compatible cannula. Patients received eladocagene exuparvovec at 1.8 × 10 11 vector genomes via the SmartFlow MR‐compatible cannula in a single operative session. Endpoints include the change from baseline in cerebrospinal fluid homovanillic acid levels, motor milestone achievement, and safety. Here we report results from 48 weeks of follow‐up. Mean (SD) cerebrospinal fluid homovanillic acid levels increased from baseline (22.5 [32.3] nmol/L; n = 13) to week 48 (55.3 [45.6] nmol/L; change from baseline: 28.3 [13.7] nmol/L; p = 0.0003; n = 9), indicating de novo dopamine production. At baseline ( n = 13), all patients showed severe motor developmental delay; at week 48 ( n = 12), nine achieved full head control, four could sit unassisted, two could stand with support, and two could walk independently to a toy. Overall, 260 treatment‐emergent adverse events were reported in 13 patients; 259 were deemed unrelated and one likely unrelated to the MR‐compatible cannula. No treatment‐emergent adverse events led to study withdrawal and no deaths occurred. This study provides further evidence of the favorable pharmacodynamic, efficacy, and safety profile of eladocagene exuparvovec in children with AADC deficiency; intraputaminal administration using an MR‐compatible cannula was well tolerated. Study GT‐002 (NCT04903288) provides further evidence of the favourable pharmacodynamic, efficacy and safety profile of eladocagene exuparvovec gene therapy in children with AADC deficiency over 48 weeks and demonstrates that intraputaminal administration using an MR‐compatible cannula was well tolerated, allowing for real‐time MRI confirmation of cannula placement and infusate coverage, and for accurate dosing to the putamen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Pediatric Neurosurgery, Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.
- Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Pediatric Neurosurgery, Dartmouth Geisel School of Medicine and Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
ORCID-Profile: Phillip L Pearl, Donald L Gilbert, Muhammad Zafar, Mered Parnes, Mariam Hull, Christian Werner, Yin-Hsiu Chien
Förderung
- PTC Therapeutics
Zitieren
APA
Curry, D. J., Pearl, P. L., Stone, S. S. D., Gilbert, D. L., Vadivelu, S., Ben-Zeev, B., Vestal, M., Zafar, M., Tai, C. H., Chou, S. C., Zibly, Z., Ungar, L., Parnes, M., Hull, M., Emrick, L., Werner, C., Krolick, A., Penematsa, V., Wang, A., …, & Hwu, P. W. (2026). Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L‐Amino Acid Decarboxylase Deficiency Using an MR ‐Compatible Cannula: 48 Weeks of Follow‐Up. Journal of Inherited Metabolic Disease, 49(2). https://doi.org/10.1002/jimd.70151
Vancouver
Curry DJ, Pearl PL, Stone SSD, Gilbert DL, Vadivelu S, Ben-Zeev B, et al. Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L‐Amino Acid Decarboxylase Deficiency Using an MR ‐Compatible Cannula: 48 Weeks of Follow‐Up. Journal of Inherited Metabolic Disease. 2026;49(2). doi:10.1002/jimd.70151
BibTeX
@article{Curry2026,
author = {Curry, Daniel J and Pearl, Phillip L and Stone, Scellig S D and Gilbert, Donald L and Vadivelu, Sudhakar and Ben-Zeev, Bruria and Vestal, Matthew and Zafar, Muhammad and Tai, Chun-Hwei and Chou, Sheng-Che and Zibly, Zion and Ungar, Lior and Parnes, Mered and Hull, Mariam and Emrick, Lisa and Werner, Christian and Krolick, Alexis and Penematsa, Vinay and Wang, Antonia and Rahman, Rezwanur and Golden, Lee and Chien, Yin-Hsiu and Hwu, Paul Wuh-Liang},
title = {Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L‐Amino Acid Decarboxylase Deficiency Using an MR ‐Compatible Cannula: 48 Weeks of Follow‐Up},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {2},
doi = {10.1002/jimd.70151}
}
EUVIMED